To include your compound in the COVID-19 Resource Center, submit it here.

Tykerb: Completed Phase III enrollment

GlaxoSmithKline completed enrollment in the double-blind, international Phase III Study 988 trial comparing 1,500 mg

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE